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(BMD) testing with dual energy x-ray absorptiometry (DXA) and received five years 
alendronate therapy if the percent young adult mean (%YAM) for BMD was less 
than 70%. Lifelong drug therapy for secondary fracture prevention was assumed 
for patients who had a osteoporotic fracture. For the base-case analysis, we ran 
the model with different age groups (65-69, 70-74, and 75-79 years). Results: 
In the women aged 65-69 years, screening strategy incurred an additional life-
time cost of $1,486 per person and conferred an additional 0.029 QALY, resulting 
in an incremental cost-effectiveness ratio of $51,195per QALY gained. For those 
aged 70-74 and 75-79 years, ICER was estimated to be $23,375 and $17,742per 
QALY, respectively. Probabilistic sensitivity analysis showed that in women aged 
65-69,70-74 and 75-79 years, screening strategy was cost-effective in 48.9%, 58.9%, 
and 59.7% of the simulations, respectively, if society is willing to pay $50,000 per 
QALY. ConClusions: Osteoporosis screening and treatment strategy would be 
cost-effective in the Japanese women aged ≥70 years.
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objeCtives: While widely perceived as a successful procedure, discectomy surgery 
has a high failure rate over time. The overall risk of recurrent disc herniation varies 
between 2-18% in reported literature. The Barricaid® anular closure device was 
designed as an adjunct to lumbar limited microdiscectomy to block large anular 
defects while maintaining as much native nucleus within the disc space. Patients 
that are considered for anular closure have a minimum posterior disc height of 
5mm, and an intra-operatively measured anular defect between 5mm and 12mm 
wide. The aim of this study was determined as to assess the cost effectiveness of the 
use of Barricaid® in this group of patients in Turkey. Methods: A simple decision 
analysis model was used to assess the cost effectiveness of the use of Barricaid®. 
The primary clinical endpoint was determined as the number of prevented rehernia-
tions. According to the literature, the use of Barricaid® reduced the number of 
reherniations by 18%. Resource utilization data were obtained via expert clinical 
opinion and included pre-op, post-op and follow-up costs, etc. Unit costs were taken 
from the Social Security Institution’s official price list. Results were presented as 
incremental cost/number of prevented reherniations. The comparison was made 
between using and not using the Barricaid®. Results: According to the results of 
the cost effectiveness analysis, the incremental number of prevented reherniation 
was 4.398 with Barricaid® and incremental cost was 119.343.000 TL. The ICER was 
within the limits of the threshold recommended by the World Health Organization 
with 27.136 TL. ConClusions: Use of Barriciad® in lumbar discectomy surgery is 
a cost-effective treatment option in Turkey.
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objeCtives: To evaluate the use of tocilizumab in Russian patients with systemic 
juvenile idiopathic arthritis (SJIA) in terms of cost-effectiveness and impact on 
social and economic burden of the disease. Methods: The model was based on 
TENDER clinical study (De Benedetti F et al., 2012). First, a pharmacoeconomical 
cost-efficiency of tocilizumab and a standard basic therapy of SJIA were com-
pared. The analysis included direct medical costs in two comparable groups (1st 
with routine administration of methotrexate and prednisolone, and 2nd with 
tocilizumab prescribed in case of refractoriness to NSAID and glucocorticoster-
oids). The efficacy of therapies was evaluated according to ACR criteria. After that, 
the influence of tocilizumab on cost and burden of illness was assessed. The 
analysis included direct medical costs and government expenditures on hospi-
talization, work incapacity insurance, monthly social pensions, benefits for care 
for a disabled children below 18 y. o. and GDP losses. 12-week time horizon was 
adopted in the CEA model, and a 1-year horizon for the assessment of burden 
of illness. Results: The cost-effectiveness in terms of ACR 90 and 70 was 4 428 
262.96 and 2 952 175.31 RUB for the group of standard treatment, and 1 166 111.66 
and 615 218.74 RUB for tocilizumab group. Tocilizumab demonstrated the same 
benefits in terms of ACR 50, 30. Analysis of burden of illness revealed a different 
structure of financial expenditures in considered strategies: pharmacotherapy 
constituted > 50% costs in tocilizumab group, but hospitalization costs were 12 
times less than in standard therapy. Annual budget losses due to social burden of 
this disease were 426 144.63 RUB per patient in the group of standard treatment 
and 226 729.10 RUB in tocilizumab group. ConClusions: The use of tocilizumab 
in SJIA is justified by better cost efficiency and reduced of social and economic 
losses of state budget connected with the burden of the disease.
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objeCtives: The present study aims to estimate the cost-effectiveness of etaner-
cept compared to golimumab in the treatment of patients with Rheumatoid 
Arthritis (RA) in Portugal. Methods: A model was adapted to assess the cost-
effectiveness of etanercept in the treatment of RA. We performed a comparison 
of the combination of etanercept + methotrexate and golimumab + methotrexate. 
Dosage of etanercept was 50mg on a weekly basis, whereas for golimumab it was 
50 mg once a month. The model is an individual simulation model and takes 
a lifetime perspective. Outcomes are expressed in QALYs, using the HAQ score 
€ 4,471 per event averted. Probabilistic and univariate sensitivity analyses were 
robust and confirmed results of the base case scenario. ConClusions: This eco-
nomic evaluation modeling suggests that celecoxib may be considered as a cost-
effective alternative vs. t-NSAIDs in the treatment of osteoarthritis in daily practice 
in the Spanish NHS.
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objeCtives: To estimate the cost-effectiveness of biologic disease modifying anti-
rheumatic drugs (bDMARDs) following failure of conventional disease modifying 
anti-rheumatic drugs (cDMARDs) in patients with severe or mild-to-severe active 
rheumatoid arthritis from a UK, NHS perspective, as part of an ongoing National 
Institute of Health and Care Excellence (NICE) appraisal. Methods: Systematic 
review of clinical effectiveness of seven bDMARDs: abatacept; adalimumab; cer-
tolizumab pegol; etanercept; golimumab; infliximab; and tocilizumab. Network 
meta-analyses (NMA) of randomised controlled trials (RCTs) reporting European 
League Against Rheumatism (EULAR) response and for RCTs reporting American 
College of Rheumatology (ACR) outcome data. An individual patient model was 
constructed to estimate costs and outcomes in terms of quality adjusted life years 
(QALY). Large observational databases, published literature and the results of the 
NMAs were used to provide data for the model. Following failure of two cDMARDs 
two broad strategies were evaluated i) a bDMARD, followed by, if necessary, rituxi-
mab then tocilizumab then cDMARDs and ii) remaining on cDMARDs. Results: 
The estimated incremental costs per QALY of bDMARD strategies compared with 
a cDMARD alone strategy were typically over £50,000 regardless of the severity 
of rheumatoid arthritis or whether the EULAR or the ACR RCTs were used. The 
cost per QALY is greater for those who receive bDMARD monotherapy. One key 
parameter affecting the results was the estimated trajectory of HAQ progres-
sion whilst a patient received cDMARDs; using rates previously assumed in NICE 
appraisals reduced estimates to approximately £30,000. ConClusions: bDMARDs 
are unlikely to be as cost-effective as has been estimated previously. The costs 
per QALYs generated within our base case analyses are greater than commonly 
reported cost-effective thresholds in England and Wales.
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objeCtives: The study aims to assess the cost-effectiveness of telerehabilitation 
for Total Knee Arthroplasty (TKA) patients in Italy. TKA was performed 64,936 
times in Italy in 2012, reasonably leading to the same number of rehabilitation 
processes. The most recent cost analysis showed rehabilitation to account for Euro 
158 million per year. Therefore, new strategies aiming at optimizing resources 
and preserve patients’ wellbeing are claimed. Methods: A four-state Markov 
model (successful TKA; revision; successful revision; death) forecasted costs 
and clinical outcome over 10 years (cycle length: 1 year) for 1,000 individuals 
undergoing usual care rehabilitation (UC) or a mixed UC-telerehabilitation (UC-T) 
program. Published literature provided transition probabilities and clinical out-
come (active knee flexion Range Of Motion-ROM); while UC and telerehabilitation 
costs were estimated through Italian tariffs and panel of experts. Each surgery 
was assumed to lead to rehabilitation or telerehabilitation, resulting in direct 
medical and indirect costs (human capital approach). Results were adjusted 
applying half-cycle correction method and discount rate of 3%. A Probabilistic 
Sensitivity Analysis described parameters uncertainty and results were reported 
using Incremental Cost-Effectiveness Ratios (ICER) from societal and Italian-NHS 
perspectives. Results: Expected mean health care costs for UC were 1,253.2€ /
patient over ten years, and UC-T costs were on average 33.7€ /patient higher (95%CI 
€ 10.8). ROM-degrees for UC and UC-T were respectively 24.5 and 26.8 (mean dif-
ference= 2.3, 95%CI 0.002). The resulting ICER was 14.5€ /ROM-degree (Italian-
NHS perspective). Adopting a societal perspective, UC-T was more effective yet 
appeared cheaper than UC (respectively 1,429 and 1,457€ /patient, mean differ-
ence -28/patient (95% CI € 10.8)). ConClusions: Although the preliminary results 
have shown that UC-T could be a cost-saving procedure if societal perspective is 
adopted; these findings are uncertain due to the model assumptions. Therefore, 
further investigations with patient-level data and generic outcome measures 
(e. g. QALY) are required to draw definitive conclusions about cost-effectiveness 
in telerehabilitation.
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objeCtives: The objective of this study was to estimate the cost-effectiveness of 
osteoporosis screening and treatment with alendronate in the Japanese women 
aged ≥65 years without a fragility fracture history. Methods: A Markov model 
with ten health states (no event, seven types of post-fracture, bedridden, and 
death) was developed to predict lifetime costs and quality-adjusted life years 
(QALY) of screening and treatment strategy, comparing with no screening. In the 
screening arm, 1,000 hypothetical cohort experienced a bone mineral density 
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objeCtives: To estimate the incremental cost-effectiveness ratio (ICER) of dual-
mobility cups (MBH) when used instead of conventional cups (FBH) to help reduce 
dislocation rates following total hip replacement (THR) in France. Methods: A 
Markov model simulated two cohorts of patients: one with MBH and one with FBH. 
Three different states of health were considered: “stable”, “dislocation/revision” and 
“death”. The model adopted a collective perspective and the time horizon of the 
model was lifetime. Dislocation/revision rates were estimated using two different 
sources: literature review and expert opinions (analysis 1) and analysis of the PMSI 
(French hospital database) of Patients having one THR in 2009 followed through the 
end of 2012 (analysis 2). Costs considered were hospitalization costs (reduction/
revision for dislocation performed in acute care unit and care in rehabilitation 
units), valued using the National Scale Costs with Common methodology (ENCC). 
Outpatients’ costs were considered for patients going back home after hospitaliza-
tion and valued by expert opinions and literature data. The model estimated the 
number of dislocations/revisions for each cohort and differences between the two 
groups in terms of QALY gained, costs and cost-effectiveness ratio. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: In analysis 
1 for a 100,000 THR cohort, 4,626 dislocations and 1,243 revisions were avoided. 
Total number of QALY gained was 894 and total economic gain € 44.7 million. In 
analysis 2, 3, 176 dislocations and 854 revisions were avoided for an economic gain 
of € 30.7 million and a gain of 611 QALY. Reported to 100,000 THR, the economic gain 
per MBH cup was € 447 or € 307. PSA estimated the mean ICER to € -55,693 per QALY 
gained. ConClusions: Because of the current rules of tariffs used in France and 
given the absence of additional costs associated with the use of DM prosthesis, this 
strategy can be considered dominant in THR.
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objeCtives: The purpose of this study was to estimate the cost-effectiveness of 
multiple anti-osteoporotic drug therapies for secondary prevention of fractures in 
elderly women with osteoporosis in Japan. Methods: A state transition model 
with nine health states (seven types of post-fracture, bedridden, and death) was 
developed to predict lifetime costs and quality-adjusted life years (QALY) of no anti-
osteoporotic therapy and eight drug therapies in patients with a previous vertebral 
fracture. Incidence of hip, vertebral, and other fracture associated with age and 
bone mineral density (BMD) was estimated by using a regression approach based 
on epidemiologic studies in Japan. Comparative effectiveness of anti-osteoporo-
tic drug therapies was derived from a published network meta-analysis. For the 
base-case analysis, we ran the model with T-score of -2.5 and different age (65, 70, 
and 75 years). Probabilistic sensitivity analysis was performed to assess param-
eter uncertainty. Results: Alendronate therapy dominated all other strategies, 
resulting in 11.746 QALY and lifetime costs of $34,568. Compared to no preventive 
therapy, alendronate conferred an additional 0.458 QALY and saved lifetime costs of 
$13,753. Risedronate was equally cost-effective, resulting in 11.731 QALY and costs 
of $34,932. Applying a willingness to pay threshold of $50,000 per QALY, the prob-
ability of being cost-effective were estimated to 76.2 % and 23.8% for alendronate 
and risedronate, respectively. These results did not change in women aged 70 and 75 
years. ConClusions: Bisphosphonate therapies for secondary prevention of frac-
tures in elderly women would be cost-effective in terms of Japan health care system.
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objeCtives: Evaluate most rationale medical technology in the rheumatoid 
arthritis therapy (RA) (comparison of alternatives – GEBDs Tofacitinib and bio-
logics: Infliximab, Abatacept, Certolizumab pegol, Golimumab, Adalimumab and 
Tocilizumab) from pharmacoeconomic analysis point of view. Methods: Analysis 
based on the assessment for one statistically average patient suffering from RA, 
and weighing 70 kilograms, over a one year course of treatment (52 weeks). The 
analysis done of direct costs included: cost of DMARDs and biologics therapy use; 
costs of drug introduction; physician visits cost. Cost-minimization and missed 
opportunities analysis were used. Results: During the effectiveness analysis 
of RA treatment, based on the meta-analyses of randomized placebo-controlled 
trials data (including meta-analyses P. Kawalec, 2013; E. Salgado, 2013), Russian 
and international RA treatment recommendations, it was concluded that there 
was no statistically significant difference in efficacy and toxicity of the Tofacitinib 
and the biologics used in the RA treatment. One year treatment course with 
Tofacitinib, Infliximab, Abatacept, Golimumab, Certolizumab pegol, Adalimumab 
and Tocilizumab cost, include subcutaneous route of administration, will amount 
to 12.818 EUR, 20.932 EUR, 14.855 EUR, 18.104 EUR, 19.642 EUR, 20.120 EUR and 21.664 
EUR, respectively. ConClusions: During pharmacoeconomic analysis was defined 
that therapy with Tofacitinib in comparison with biologics use will reduce the cost 
of a one year course of treatment for each RA patient from 2.037 EUR to 8.846 EUR. 
Transition of 100 RA patients onto a treatment regimen, includes Tofacitinib use, 
will make it possible to treat from 15 to 69 patients more suffering from this disease.
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to measure quality of life. The clinical parameters used in the model take into 
account the results from a MTC of clinical trials. In order to adapt the model to 
the Portuguese context, several adjustments were made to its original version. 
These mainly relate to mortality rates by gender and to the unit costs of medical 
resources, such as drugs, medical visits, admissions, ancillary tests and so on, 
that were obtained from public official sources. We applied a 5% discount rate and 
conducted an analysis for a hypothetical cohort of 1,000 patients. Results: The 
treatment of RA with etanercept is more expensive than that with the comparator. 
Nevertheless, QALYs gained do compensate for the additional costs. Overall, ICER 
is € 12,853, which is below the usual willingness to pay threshold used in Portugal. 
A sensitivity analysis was carried out, which confirmed the robustness of these 
results. ConClusions: According to our analysis, etanercept is a cost-effective 
alternative versus golimumab for the treatment of rheumatoid arthritis. Its main 
advantage over the selected comparator relates to the associated improvements 
in health related quality of life.
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objeCtives: To determine the cost-effectiveness of pegloticase (Krystexxa®) for 
patients with severe debilitating chronic tophaceous gout (SDCTG), from a UK health 
care perspective. Methods: Severe debilitating chronic tophaceous gout (SDCTG) 
is a debilitating disease, with high unmet medical need. Existing treatments mainly 
provide symptom relief and do not modify the disease course. Pegloticase has the 
potential to be a disease modifying agent. A decision analytical model was built to 
compare the use of pegloticase in patients with SDCTG with best supportive care 
(BSC) with a Markov model used to extrapolate outcomes to a 20 year time-horizon. 
In the basecase, the disease modifying properties of pegloticase were modelled. 
In scenario analyses only symptomatic relief of pegloticase on acute attacks and 
tophi was included. Results: In the basecase, the cost-effectiveness of pegloti-
case compared to BSC was £31,027 per QALY gained. In this basecase, pegloticase 
dramatically reduced the uric acid burden in over 60% of patients who completed a 
six month course and were assumed could then be controlled on xanthine oxidase 
inhibitor maintenance treatment. In a pessimistic scenario whereby pegloticase was 
assumed to only provide symptomatic relief, the ICER was £48,672/QALY gained. In a 
further scenario whereby utility benefits were limited to only short-term reduction 
in acute flares and presence of tophi, the ICER was £54,345/QALY. Apart from these 
two drivers, the cost-effectiveness estimates were relatively stable across a range 
of sensitivity analyses. ConClusions: In the context of a highly severe and debili-
tating form of gout, with small patient numbers and a lack of alternative effective 
treatment options, pegloticase can be considered good value-for-money. Further 
clinical evidence is required to demonstrate the disease modifying properties of 
pegloticase. However, such data collection and hence the ability to perform robust 
economic evaluations for HTA purposes is difficult especially when the sponsoring 
company is small with limited funds.
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objeCtives: The prevalent vertebral fracture (VF) is a risk factor for future VF, which 
can be decreased with drug therapy. However, most VFs are not recognized clinically. 
Vertebral fracture assessment (VFA) by dual-energy x-ray absorptiometry (DXA) and 
spine x-ray can be performed to detect these prevalent VFs. This study aimed to 
estimate the costs, effectiveness, and radiation exposure of VF diagnostic strate-
gies. Methods: Markov model over a 10-year period was used to calculate the 
medical costs for diagnostic tests and VF treatment, the reduction of incident VFs 
of patients who have experienced a VF, and the radiation doses in target population 
aged over 50. We compared three strategies: ‘VFA followed by confirmatory radi-
ography (VFA screening)’, ‘only VFA’ and ‘only x-ray’ every 2 years, to ‘no screening 
before recognition’. We assumed that all patients tested positive for VF received drug 
therapy. A discount rate of 5% was applied in cost. Results: The results showed the 
incremental costs for women over age 50 who had VFA screening, only VFA, and only 
x-ray were $1,112, $1,546, and $1,270 per person, respectively. Future VF incidence 
was reduced by 29% in both VFA screening and only VFA and 35% in only x-ray as 
compared with no screening for 10 years. Radiation exposure was highest in the 
only x-ray strategy. Also, the effectiveness and medical costs were more increased 
in female and old age people than in male and over age 50. The sensitivity analyses 
showed that these results are robust to variety assumptions including cycle length, 
medical costs, and diagnostic accuracy. ConClusions: This study suggests that 
VFA screening strategy can be relevant option for new VF prevention as considering 
lower cost and less radiation. This study is expected to provide useful information 
as establishing the VF diagnostic strategy in clinical practice.
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